This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Research led by internist-nephrologist Dr. Michele Eisenga shows that SGLT2 inhibitors, a class of drugs widely used to treat type 2 diabetes, heart failure and chronic kidney disease, consistently increase hemoglobin and hematocrit levels.

By combining data from 85 randomized clinical trials involving more than 70,000 participants, the researchers found that these drugs consistently increase hemoglobin and hematocrit levels and may influence the way the body regulates iron and produces red blood cells. The study is published in the JAMA.

People with chronic kidney disease and heart failure frequently develop anemia, a condition characterized by low hemoglobin levels and reduced oxygen transport throughout the body. Previous clinical trials had already shown that patients receiving SGLT2 inhibitors experienced increases in hemoglobin and hematocrit, but the magnitude and underlying mechanisms of these changes remained unclear.

To better understand these effects, Eisenga and colleagues performed a systematic review and meta-analysis of 85 randomized clinical trials, including 70,543 participants with diabetes, cardiovascular disease, heart failure and chronic kidney disease. Compared with placebo or other glucose-lowering medications, SGLT2 inhibitors were consistently associated with higher hemoglobin and hematocrit levels after a median follow-up of 24 weeks. The increase was modest but consistent across studies. On average, hemoglobin levels increased by 0.60 g/dL and hematocrit by 2.36% compared with control groups.

The researchers also investigated markers involved in iron metabolism and red blood cell production.

Source link